1487P Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer: Updated results.
Saved in:
| Title: | 1487P Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer: Updated results. |
|---|---|
| Authors: | Wang, Q.1 (AUTHOR), Xu, A.2 (AUTHOR), Ma, C.3 (AUTHOR), Wang, T.4 (AUTHOR), Liu, P.5 (AUTHOR), Duan, Y.6 (AUTHOR), Kong, T.7 (AUTHOR), Chen, G.8 (AUTHOR), Jia, X.9 (AUTHOR), Shang, K.10 (AUTHOR), Yang, G.11 (AUTHOR), Zhang, G.12 (AUTHOR), Yu, F.13 (AUTHOR), Wang, H.14 (AUTHOR), Chen, H.15 (AUTHOR) |
| Source: | Annals of Oncology. 2023 Supplement 2, Vol. 34, pS840-S840. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2023.09.2518 |
